Amgen to Present Innovations in Autoimmune Disease Research at ACR Convergence 2026

Amgen at ACR Convergence 2026

Amgen, a leader in biotechnology, has announced its plans to showcase groundbreaking data regarding rare and serious autoimmune diseases during the upcoming ACR Convergence 2026 conference. This event is anticipated to take place from November 8-11, 2026, in the heart of the medical community. Amgen's presentation will include key findings from the Phase 3 OASIZ-301 study, which focuses on treatment advancements for Sjögren's disease, among other serious autoimmune conditions.

Highlights of Amgen's Findings

One of the pivotal studies being highlighted relates to Dazodalibep, a promising treatment for Sjögren's disease—a systemic autoimmune condition characterized by severe dryness and significant impacts on quality of life. The Phase 3 OASIZ-301 trial demonstrated that both dosing regimens of Dazodalibep (1,500 mg every four weeks and 3,000 mg every 12 weeks) resulted in statistically significant reductions in systemic disease activity. Notably, these improvements were evident much sooner than anticipated, within just four weeks of starting the treatment.

Dr. Teresa K. Tarrant, an Associate Professor of Medicine at Duke University, noted, "For patients living with Sjögren's disease, disease activity and symptoms can have a significant impact on their health and daily lives. The rapid improvements we’re observing with Dazodalibep are particularly encouraging, indicating meaningful advancements in managing this challenging disease."

The study recorded patients exhibiting an average ESSDAI score of 10.2 at the start. By the end of the 48 weeks, there was a notable decline of at least five points in disease activity scores, showcasing the potential of Dazodalibep as a vital option for those affected by Sjögren's disease, for which there are currently no FDA-approved treatments.

Broader Implications of the Presentation

In addition to the groundbreaking work surrounding Dazodalibep, Amgen will also present long-term safety data from its UPLIZNA trial for patients with IgG4-related disease and real-world evidence for KRYSTEXXA® and TAVNEOS®. This multi-faceted approach demonstrates Amgen's extensive commitment to addressing unmet needs within the realm of autoimmune diseases and reinforces the company’s mission to improve patient outcomes through innovative therapies.

The insights planned for release at ACR 2026 aim to showcase not only the potency of these treatments but also their potential to significantly enhance patient quality of life. By illustrating real-world effectiveness alongside clinical trial data, Amgen aspires to present a thoroughly researched narrative that addresses the complexity of autoimmune diseases.

Dr. Paul Burton, Amgen's Chief Medical Officer, expressed confidence in the findings: "The range of data we’re presenting at ACR reflects our commitment to the autoimmune disease community, highlighting the importance of advancing innovative therapies through rigorous scientific research and real-world evidence."

What to Expect at ACR 2026

Attendees at the ACR Convergence 2026 can look forward to detailed presentations, discussions, and poster sessions featuring Amgen’s latest research. With multiple abstracts planned, participants will have opportunities to engage with the scientific community on significant advancements in treatment modalities for challenging autoimmune conditions.

In summary, Amgen is poised to make a considerable impact at ACR 2026 by unveiling new insights and progress in treating rare autoimmune diseases. The data presented are expected to not only enhance understanding but also to push the boundaries of therapeutic potential, ensuring better management of these prevalent yet under-recognized diseases. All eyes will surely be on Amgen as it reveals the future of autoimmune disease treatment at this important gathering.

Amgen remains committed to pioneering new pathways in medical research, exploring ways to dramatically improve the lives of those affected by autoimmune diseases, and their presence at ACR 2026 is a testament to this ongoing dedication.